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Introduction: Proper functioning of the luteinizing hormone/chorionic  gonadotrophin 
receptor (LHCGR) is essential for male sexual differentiation and maintenance of normal 
testosterone levels, as well as for ovarian function and fertility in females. Completely 
inactivating mutations of the LHCGR gene in 46,XY individuals lead to Leydig cell 
hypoplasia type 1, characterized by a female phenotype without signs of pubertal 
development, presence of testicular intra-abdominal remnants and absence of Mullerian duct 
derivatives. 
Due to their important role in reproduction, inactivating mutations of the LHCGR gene are 
very rarely encountered in clinical settings.  
 
Aim of the work: To study a case of male pseudohermaphroditism caused by a novel LHCGR 
mutation and explain the mechanism by which this mutation leads to Leydig cell hypoplasia 
type 1.  
 
Methods: Sequencing of the LHCGR gene was done. Functional studies were performed after 
transfection of HEK293 cells with the mutant and wild-type (WT) LHCGR gene. Generation 
of cAMP was measured under stimulation by agonists. This was also performed after 
preincubation with an allosteric LHCGR agonist known to facilitate proper folding of 
misfolded LHCGR mutants. Membrane localization of the mutant receptor was analyzed by 
flow cytometry and immunocytochemistry. Also, the capacity of the mutant receptor to be 
activated in the endoplasmic reticulum by co-expression of hCG was tested. 
 
Results: A novel mutation of the LHCGR gene (1850delG) was identified in a homozygous 
state. The deletion causes a frame-shift mutation and a prematurely truncated protein.  
cAMP generation was significantly reduced for the mutant receptor compared to WT. Also, 
despite preincubation with the allosteric agonist, cAMP generation did not improve in the 
1850delG cells. Flow cytometry and immunocytochemistry revealed that the 1850delG 
mutant receptor was not found on the cell surface, unlike WT LHCGR. However, the mutant 
receptor was detected in permeabilised cells. Co-transfection of culture cells with the LHCGR 
and hCG genes did not lead to cAMP generation in the 1850delG cells.    
 
Conclusions: We present a novel LHCGR inactivating mutation in a patient with female 
phenotype, but 46,XY karyotype. This is one of few frame-shift LHCGR mutations described. 
The functional studies found that the mutant receptor cannot reach the cell membrane and is 
incapable of signaling, most likely due to its profoundly altered tertiary structure.  
